News

Video

Moonshot Cancer Initiative and MCED Consortium: Advancing Cancer Detection

Author(s):

Elizabeth O’Donnell, MD, Dana-Farber Cancer Institute,Jon O. Ebbert, MD, Mayo Clinic

Explore the pivotal role of the Moonshot Cancer Initiative and MCED Consortium in shaping the landscape of early cancer detection and screening, with a focus on innovative screening tools and legislative support.

Related Videos
Elizabeth Buchbinder, MD
3 experts are featured in this series.
Grzegorz S. Nowakowski, MD, and Samuel Yamshon, MD, break down the current treatment landscape for relapsed/refractory follicular lymphoma.
2 experts in this video
2 experts in this video
Javier Pinilla, MD, PhD, and Talha Badar, MBBS, MD, discuss factors that influence later-line treatment choices in chronic myeloid leukemia.
Javier Pinilla, MD, PhD, and Talha Badar, MBBS, MD, on the implications of the FDA approval of asciminib in newly diagnosed CP-CML.
Erica L. Mayer, MD, MPH, director, clinical research, Dana-Farber Cancer Institute; associate professor, medicine, Harvard Medical School
Related Content
Maximilian Stahl, MD
December 18th 2024

Menin Inhibitor–Based Combinations Are Central to Ongoing Research in KMT2A+/NPM1+ AML

OncLive On Air
September 11th 2024

Oncology Experts Preview Top Abstracts From the 2024 ESMO Congress

Ann Partridge, MD, MPH, of Dana-Farber Cancer Institute
December 12th 2024

Study Finds Quality of Life Maintained With Active Monitoring for DCIS

Narjust Florez, MD
September 5th 2024

Florez Focuses on Patient-Centered NSCLC Biomarker Testing Discussions

Dana-Farber Researchers to Present Findings at 2024 San Antonio Breast Cancer Symposium
December 11th 2024

Dana-Farber Researchers to Present Findings at 2024 San Antonio Breast Cancer Symposium

Chronic Lymphocytic Leukemia | Image Credit: © LASZLO– stock.adobe.com
December 8th 2024

Fixed-Duration Acalabrutinib/Venetoclax Combo Improves PFS in Frontline CLL